Enlivex Therapeutics Ltd Cash Flow Conversion Efficiency
Enlivex Therapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, Enlivex Therapeutics Ltd (ENLV) has a cash flow conversion efficiency ratio of -0.131x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.30 Million ≈ $-6.15K USD) by net assets (ILA17.48 Million ≈ $46.87K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Enlivex Therapeutics Ltd (2012–2024)
Cash flow conversion efficiency of Enlivex Therapeutics Ltd from 2012 to 2024. This chart illustrates how Enlivex Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ENLV share price today for real-time trading data and today's change.
Enlivex Therapeutics Ltd Cash Flow Conversion Ratio Explained
Enlivex Therapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Enlivex Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enlivex Therapeutics Ltd ranked by their cash flow conversion efficiency. Also see ENLV stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lexington Gold Ltd
LSE:LEX
|
-0.028x |
|
QUICKBIT EU AB O.N.
F:QBT
|
-0.500x |
|
Safe Orthopaedics SA
PA:ALSAF
|
0.143x |
|
Haydale Graphene Industries
LSE:HAYD
|
-0.398x |
|
The Investment Company plc
LSE:INV
|
-0.009x |
|
Biosergen AS
ST:BIOSGN
|
-0.954x |
|
Sumo Resources PLC
PA:MLSUM
|
N/A |
|
IQ-AI LTD. LS -01
F:5Y1
|
N/A |
Annual Cash Flow Conversion Efficiency for Enlivex Therapeutics Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Enlivex Therapeutics Ltd from 2012 to 2024. Review ENLV free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA23.59 Million ≈ $63.24K |
ILA-13.01 Million ≈ $-34.87K |
-0.551x | +29.47% |
| 2023-12-31 | ILA30.08 Million ≈ $80.65K |
ILA-23.52 Million ≈ $-63.06K |
-0.782x | -85.55% |
| 2022-12-31 | ILA56.84 Million ≈ $152.39K |
ILA-23.95 Million ≈ $-64.22K |
-0.421x | -104.29% |
| 2021-12-31 | ILA85.04 Million ≈ $227.99K |
ILA-17.54 Million ≈ $-47.03K |
-0.206x | +33.49% |
| 2020-12-31 | ILA35.49 Million ≈ $95.14K |
ILA-11.01 Million ≈ $-29.51K |
-0.310x | +50.30% |
| 2019-12-31 | ILA11.28 Million ≈ $30.25K |
ILA-7.04 Million ≈ $-18.88K |
-0.624x | -91.63% |
| 2018-12-31 | ILA9.71 Million ≈ $26.02K |
ILA-3.16 Million ≈ $-8.47K |
-0.326x | +83.79% |
| 2017-12-31 | ILA3.16 Million ≈ $8.48K |
ILA-6.35 Million ≈ $-17.03K |
-2.009x | -12.84% |
| 2016-12-31 | ILA8.70 Million ≈ $23.32K |
ILA-15.49 Million ≈ $-41.52K |
-1.780x | -140.94% |
| 2015-12-31 | ILA17.93 Million ≈ $48.08K |
ILA-13.25 Million ≈ $-35.52K |
-0.739x | -414.03% |
| 2014-12-31 | ILA30.67 Million ≈ $82.24K |
ILA-4.41 Million ≈ $-11.82K |
-0.144x | +7.69% |
| 2013-12-31 | ILA5.55 Million ≈ $14.89K |
ILA-865.00K ≈ $-2.32K |
-0.156x | +92.16% |
| 2012-12-31 | ILA75.00K ≈ $201.07 |
ILA-149.00K ≈ $-399.46 |
-1.987x | -- |
About Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee o… Read more